GRM1 and depressive symptom measurement: We next sought to determine which formulation was superior in treating mild-to-moderate COVID-19 with symptoms of depression (Asadi-Pooya & Simani, 2020; Havervall et al., 2021) or inflammation via targeting specific targets (GRM1, GRM5, mTOR and PLA2G4A).